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Abstract
Purpose Primary antibody deficiency patients suffer from in-
fectious and non-infectious pulmonary complications leading
over time to chronic lung disease. The complexity of this
pulmonary involvement poses significant challenge in differ-
ential diagnosis in patients with long life disease and increased
radio sensitivity. We planned to verify the utility of chest
Magnetic Resolution Imaging with Diffusion-Weighted
Imaging as a radiation free technique.
Methods Prospective evaluation of 18 patients with Common
Variable Immunodeficiency and X-linked Agammaglobulinemia.
On the same day, patients underwent Magnetic Resonance
Imaging with Diffusion Weighted Imaging sequences, High
Resolution Computerized Tomography and Pulmonary
Function Tests, including diffusing capacity factor for
carbonmonoxide. Images were scored using a modified ver-
sion of the Bhalla scoring system.
Results Magnetic Resonance Imaging was non-inferior to High
Resolution Computerized Tomography in the capacity to identi-
fy bronchial and parenchymal abnormalities. HRCThad a higher
capacity to identify peripheral airways abnormalities, defined as
an involvement of bronchial generation up to the fifth and distal
(scores 2–3). Bronchial scores negatively related to pulmonary
function tests. One third of consolidations and nodules had
DiffusionWeighted Imaging restrictions associated with system-
ic granulomatous disease and systemic lymphadenopathy. Lung
Magnetic Resolution Imaging detected an improvement of bron-
chial and parenchymal abnormalities, in recently diagnosed pa-
tients soon after starting Ig replacement.
Conclusions Magnetic Resonance Imaging with Diffusion
Weighted Imaging was a reliable technique to detect lung
alterations in patients with Primary Antibody Deficiencies.
Keywords Primary antibody deficiencies . lung
abnormalities . magnetic resonance . diffusionweighted
imaging . inflammation . GLILD
Introduction
Patients with X-linked Agammaglobulinemia (XLA) and
Common Variable Immunodeficiency (CVID) suffer from re-
current respiratory infections and non-infectious pulmonary
diseases possibly leading, over time, to permanent lung damage
[1–4]. Common lung alterations are bronchiectasis, bronchial
wall thickening, nodules and parenchymal consolidations [5,
6]. Moreover, patients with primary antibody deficiencies
(PAD) are affected also by a group of lung diseases,
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denominated granulomatous-lymphocytic interstitial lung dis-
ease (GLILD) [7–11] characterized by granulomatous and pul-
monary lymphoid hyperplasia, histological patterns consisting
of lymphocytic interstitial pneumonia (LIP), follicular bronchi-
olitis, and lymphoid hyperplasia [12]. The complexity of this
pulmonary involvement poses a significant challenge in differ-
ential diagnosis [13]. Physical examination, laboratory analysis
and Pulmonary Function Tests (PFTs) are routinely used in the
work-up of PAD lung disease, but High Resolution Computed
Tomography (HRCT) is often required to establish a definite
diagnosis. HRCT scan is the gold standard for the assessment
of lung diseases. Because of the long life course of PAD, pa-
tients undergo a considerable number of radiological examina-
tions during their life. As an increased radio sensitivity has been
described [14–19], clinicians should consider a risk-benefit as-
sessment when ordering a CT scan. We have already shown
that Magnetic Resonance Imaging (MRI), a radiation-free tech-
nique was complementary or alternative to HRCT scan [20] to
detect lung alterations. However, chest HRCT scan and mor-
phological MRI sequences did not give information on the
presence of foci of active inflammation and often invasive
methods as lung biopsy or bronchoalveolar lavage are neces-
sary [13]. Functional MRI with diffusion-weighted imaging
(DWI) sequences might represent a promising tool for the iden-
tification of areas of active inflammation/sub clinical infections
in lung parenchyma [21]. DWI signal derives from the free
motion of water molecules in tissues. The interaction with an
increased number of cells or macromolecules leads to a restric-
tion of this motion, with higher DWI signal intensity. DWI has
been validated as diagnostic tool in various inflammatory dis-
eases in the abdomen, pelvis and brain [22–24].
In lung imaging, DWI has been applied in the differential
diagnosis of lung consolidations and neoplasms, based on the
fact that the signal intensity is higher in viable tumour tissues
than in less densely packed tissues, such as tumour necrosis or
benign consolidations [25–27].
Following these considerations, we have introduced DWI
in our diagnostic approach for PAD patients. The objective of
this study was to evaluate if chest MRI with DWI may repre-
sent a feasible radiation free option in the evaluation of PAD
lung disease.
Methods
Study Design We set out a prospective single center study,
enrolling 18 consecutive patients aged >18 years with an
established diagnosis of PAD [28] and recurrent respiratory in-
fection. On the same day, patients underwent chest MRI without
contrast medium and including DWI sequences and Pulmonary
Function Tests (PFTs), including diffusing capacity factor for
carbon monoxide (DLCO). To validate the MRI score, a chest
HRCT scan was performed. Examinations were carried out far
from clinical evidence of acute pulmonary infection. Data on
clinical manifestation and immunoglobulin replacement were
collected by medical records. Immuno-phenotyping of peripher-
al bloodmononuclear cells was also performed. The institutional
review board approved the study and a signed informed consent
was obtained from all participants.
HRCTStudy HRCT images were acquired with a 64-detector
row spiral CT scanner (Volume Sensation Cardiac; Siemens),
without injection of IV contrast agent, from the lung apices to
the upper abdomen in a single breath-hold at the end of full
inspiration. The parameters used for acquisition were as fol-
lows: 100 kV, CAREdose (Siemens) with quality reference
set at 100 mAs; collimation, 64×0.6 mm; gantry rotation time,
0.33 s; scan time, 6 s; reconstruction kernel, B30 (for medias-
tinal evaluation) and B60 (for lung parenchyma evaluation).
MRI Study MRI images without contrast medium were ob-
tained with a 1.5 Tesla scanner (Magnetom Avanto, Siemens,
Enlargen, Germany) using a respiratory triggered DP weight-
ed BLADE sequence (TR:2000 ms; TE=27 ms; FOV
400 mm; flip angle: 150°; slice thickness 5 mm) acquired on
an axial plane. DWI sequence (TR: 5632 ms, 12; TE: 83 ms;
flip angle: 90°; FOV 400 mm slice thickness 5 mm; b0-b800
s/mm2) on an axial plane was included in the acquisition
protocol. A combination of two surface coils covering the
whole thorax and the spine was used.
Image Analysis MRI and CT scan studies were scored
adopting the Bhalla score [20, 29] in a random order by two
chest radiologists, blinded to patients’ identities and clinical
information. Readers evaluated each examination indepen-
dently and separately and reached an agreement for the con-
troversial lesions. In order to reduce recall bias effects from
the remembering of MRI findings, HRCT scans were evalu-
ated 4 weeks after the analysis of the MR images. DWI ab-
normalities (hot spots) were identified as areas showing equal
or higher signal intensity compared to the spinal cord at the
highest b value [26]. An eyeballing comparison was per-
formed between DWI and morphological-MRI in order to
identify the morphological substrate of the diffusion abnor-
malities observed in consolidations or nodules.
Bhalla Score Classical Bhalla score evaluated severity and
extent of bronchial and parenchymal parameters [29].
Bronchial parameters were: a) bronchiectasis severity, b) extent
of bronchiectasis (number of lung segments), c) peribronchial
thickening, d) extent of mucus plugs (number of lung seg-
ments), e) generation of bronchial division involved (bronchi-
ectasis/plug). Parenchymal parameters were: a) abscesses or
sacculations (number of lung segments), b) numbers of bullae,
c) emphysema (number of lung segments), d) collapse/consol-
idations. Two extra parenchymal categories were introduced
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for the assessment of nodules: nodule number (score 0: no
nodules detected; score 1: < 5 nodules detected; score 2: > 5
nodules detected) and size: (score 1: < 1 cm; score 2: > 1 cm).
The cut-off diameter discriminating between nodules and con-
solidations was up to 30mm. Total bronchial score (min 0; max
15) was defined as the sum of each bronchial parameter score;
total parenchymal score (min 0; max 14) was defined as the
sum of each parenchymal parameter score; total Bhalla score
was defined as the sum of bronchial and parenchymal scores.
PFTs The PFTs were performed at the Pulmonary Function
Unit. We analysed the following data sets: 1) forced vital
capacity (FVC), 2) forced expiratory volume in one second
(FEV1); 3) forced expiratory flow between 25 and 75 %
(FEF25–75); 4) corrected DLCO.
Flow Cytometry Analysis Peripheral blood mononuclear
cells were obtained by density-gradient centrifugation.
Immunophenotyping was performed with the combination
of 4 fluorochrome-labeled monoclonal antibodies (BD
Biosciences). The following B-cell populations were
analysed: classical naïve (CD19+CD27−CD21+CD38+),
switched memory (CD19+CD27+CD21+IgM−), IgM memory
( C D 1 9 + C D 2 7 + I g M + I g D + ) , t r a n s i t i o n a l
(CD19+IgM++CD38++) and CD21low (CD19+CD21−/
lowCD38−). Dead cells were excluded from analysis by side/
forward scatter gating. FACS analyses were performed on a
FACSCalibur instrument (BD Biosciences) using the
CellQuest (BD) and FlowJo (Tree Star) software.
Statistical Analysis Statistical analysiswas performed by using
a dedicated software (StatView). Descriptive data were presented
as median and interquartile range (IQR), as indicated.
Comparison of clinical and radiological changes between groups,
was performed by Mann-Whitney test. Comparison of categori-
cal and non-continuous variables between groups was performed
Fig. 1 HRCT and MRI score comparison a Number of patients with
primary antibody deficiency and defined bronchial abnormality score
(generalities of the bronchial division, bronchiectasis severity, extent of
bronchiectasis, peribronchial thickening, mucus plugs) identified by
HRCT scan and MRI. b Number of patients with primary antibody
deficiency and defined parenchymal abnormality score (abscesses,
consolidations, bullae, emphysema, nodules number and dimension)
identified by HRCT scan and MRI. Gray bars refer to MRI data; black
bars refer to HRCT scan data
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by chi-square test. Comparison of MRI and HRTC scores was
performed by chi square test to assess MRI non-inferiority.
Comparison between single PFTs parameter and MRI score
was assessed by simple linear regression analysis. A p value of
<0.05 was taken as the threshold of statistical significance.
Inter-observer agreement was evaluated comparing the
HRCT and MRI total scores (TOT) calculated by the 2
readers; intra-observer variability was evaluated comparing
the two different readings of the same HRCT and MRI
datasets performed by the most experienced radiologist after
an interval of at least 4 weeks. The intra- and inter-observer
agreement for scoring values were analysed by the use of
Intraclass Correlation Coefficient (ICC).
Results
Patient Population Eighteen (13 males, 5 females) PAD pa-
tients were enrolled in the study: 16 patients had a diagnosis of
CVID and two patients of XLA. The median age at the study
time was 39.5 years (IQR 30.5–55). At the enrolment, 14
patients received Ig replacement therapy administered intra-
venously (IVIG) and two patients subcutaneously (SCIG); 2
patients (n.4 and 9) were newly diagnosed CVID and they
started the IVIG substitutive treatment at the time of the study,
reaching a plateau of trough IgG level 3 months thereafter.
PAD-associated clinical conditions were: autoimmune disease
(8/18 patients), chronic lymphadenopathy (10/18 patients),
splenomegaly (11/18 patients), systemic granulomatous dis-
ease (seen by histology – 4/18) and chronic obstructive lung
disease (COPD) (7/18 patients). Relevant clinical and immu-
nologic data were summarized in Supplementary Table 1. All
patients with COPD diagnosis were on treatment with long-
acting inhaled therapy (beta-agonists and steroids and/or anti-
cholinergics). None of our patients were on treatment with
systemic steroids and/or immunosuppressive drugs. Overall,
on PFTs, FEV1 was 68% (IQR 45–85%), FVC: 70.5 % (IQR
53–81 %), FEV1/FVC: 97 % (IQR 73–107 %), PEF: 64 %
(IQR 43–79 %), FEF 25–75: 71 % (IQR 32–98 %); DLCO
(corrected): 91.6 % (IQR 78.6–96.7 %).
CT and MRI: Image Acquisitions Room time for CT scan
was 4.1 min (IQR 3.9–5.2) and the dose length product was
104 mGy×cm (IQR: 90–113); effective dose was 1.3 mSv
(IQR: 0.9–1.8). MRI room time was 17 min (IQR 12–20).
Intra-observer agreement was calculated to assess reproducibility
of the newly developed DWI scoring system. A good inter-
observer agreement was found for both bronchial and parenchy-
mal MRI scores (ICC for Total Score: 0903 and 0942 respec-
tively). A good inter-observer agreement was observed for DWI
scores (ICC for Total DWI score: 0975). A good inter-observer
agreement between the two readers was found in the scoring
evaluation of HRCT studies (ICC for Total Score: 0971).
Lung Abnormalities by MRI Mean total score recorded by
MRI was 8 (IQR 5–11). Bronchial abnormalities and paren-
chymal abnormalities were evident in 78 % and in 66.7 %
patients, respectively. Individual bronchial and parenchymal
MRI scores were shown in Supplementary Table 2. Mean total
bronchial MRI score was 6 (IQR 3.25–9). Bronchiectasis,
mucus plugging, peribronchial thickening were detected in
77.8, 55.5 and 66.7 % of patients, respectively. As expected,
PAD patients with COPD had higher total MRI bronchial
scores (9, IQR 7–11) in comparison to patients without
COPD (5, IQR 1.5–6) (p=0.033). Total MRI parenchymal
scores were 2 (IQR 0–6). None of the patients had bullae or
abscesses; 16.7 % patients had emphysema. Consolidations
and nodules were recorded in 50 and 55.5 % patients, respec-
tively. The cumulative number of consolidations was 41 and
of nodules was 40.
HRCTand MRI Comparison in Lung Abnormalities
Evaluation
Bronchial abnormalities were the most common lung alterations
recorded in PAD patients by HRCT scan (89 %). We observed
high levels of concordance between HRCT and MRI in scoring
bronchiectasis severity (p=0.0004), extent of bronchiectasis
(p<0.0001) and mucus plugging (p<0.0001). A lower but still
significant level of concordance was found between HRCT and
MRI in the capacity to score the bronchial division involvement
(p=0.02), in that HRCT had a higher capacity (p=0.02) to iden-
tify peripheral airways abnormalities, defined as an involvement
of bronchial generation up to the fifth and distal (scores 2–3)
detected in 83 and 61 % of patients, respectively.
We observed high levels of concordance between HRCT
and MRI in scoring parenchymal abnormalities: consolida-
tion, p<0.0001; nodule number, p<0.0001; nodule dimen-
sion, p<0.0001; emphysema, p<0.0001). Ten out of 18 pa-
tients had at least a nodule identified by HRCT and MRI.
Nodule dimension was similarly scored with exception of
two patients with small nodules (diameter <1 cm) identified
by HRCT scan only. Figure 1 shows the comparison between
HRCT scan and MRI scores. Supplementary Table 2 shows
individual scores by MRI and HRCT scan.
PFTs and Lung Radiological Abnormalities by
MRI Overall, a statistically significant negative correlation
was found between total bronchial scores and PFTs parame-
ters (FEV1, r2=0.42 p=0.003; FVC, r2=0.45 p=0.002; PEF,
r2=0.4 p=0.006). In detail, FEV1 was negatively related with
all bronchial parameters; FVC was negatively related with
Fig. 2 Pulmonary Function Test and Bhalla bronchial score Linear
regression analysis of PFTs and bronchial parameters by MRI scored
according to Bhalla; r2 and p value are indicated for each parameter
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bronchiectasis severity, bronchiectasis extension, bronchial
wall thickening; FEF 25–75 was negatively related with mu-
cus plugging only (Fig. 2). Three patients (n. 4, 5, 10) with
normal PFTs parameters had bronchial abnormalities (mucus
plugging and bronchial wall thickening) detectable by MRI.
Total parenchymal scores did not show any correlation
with PFTs, including DLCO.
MRI DWI Study Six out of nine patients with consolidations
recorded by MRI had DWI hotspots. Overall, 14 out of 41
consolidations recorded (34.1 %) were DWI restricted
(Fig. 3a). DWI hotspots were related to consolidations with a
MRI score <1 (segmental or lobar extension). All consolida-
tions with a MRI score of 1 (sub-segmental extension) were
DWI negative. Four out of ten patients with nodules had DWI
hotspots. Overall, 13 out of 40 nodules recorded by MRI
(32.5 %) were DWI-restricted (Fig. 3b). Nodules had a maxi-
mum transversal diameter ranging between 3 and 14 mm.
There was no difference in the mean diameter between nodules
with or without DWI hotspots (7 mm, IQR 6–8, vs 5.5 mm,
IQR 4.75–7). In Fig. 4 and Fig. 5, we show representative
MRIs with DWI-restricted and DWI-non restricted areas.
Patients with DWI hotspots had higher total MRI Bhalla score
and higher total MRI parenchymal scores in comparison to
Fig. 3 Parenchymal abnormalities with and without DWI hotspots
Number of consolidations (a) and nodules (b) with or without DWI hot
spots in PAD patients.Grey box refer to the number of lung abnormalities
without DWI hotspots; black box refer to the number of lung alterations
with DWI hotspots (y-axis). Numbers on the x-axis refer to patients
identification number (ID)
Fig. 4 Representative MRI with
DWI sequences: consolidations
Consolidations detected by MRI
with DWI. MRI BLADE
sequence showed bilateral,
chronic collapses of lower lobes
(white arrow) (a) without DWI
corresponding hotspots (b). MRI
BLADE sequence showed a
consolidation (white arrow) of the
left lower lobe (c) with a
corresponding hotspot at the DWI
assessment (white arrow) (d). The
histology of this consolidation by
lung biopsy is shown in
Supplementary Fig. 1
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patients who did not have DWI-restricted parenchymal areas
(total score 10 (IQR 7.5–16) vs 6 (IQR 2.5–8.5) (p=0.05); total
parenchymal score 5 (IQR 3.5–6) vs 0 (IQR 0–0.75), respec-
tively). Patients with DWI-restricted consolidations had also a
lower predicted FEV1% in comparison to patients without
DWI hotspots (45 %, IQR 34–71 % vs 81 %, IQR 60.8–
85 %). DWI restricted abnormalities (nodules and/or consoli-
dations) were only detected in patients with systemic granulo-
matous diseases. Isolated DWI restricted consolidations were
mainly present in patients with systemic lymphadenopathy
(85 % vs 36 %, p=0.04). The presence of DWI-restricted areas
was not associated with splenomegaly and autoimmune mani-
festations. Moreover, patients with DWI-restricted abnormali-
ties had an increased percentage of CD21low B cells in com-
parison to patients without DWI hot spots (33%, IQR 23.5–47,
vs 16 %, IQR 14–21, p=0.05). The analysis of other B and T
cell subsets did not show any differences between patients with
DWI restricted and not restricted areas.
Only one patient (n. 4) underwent a lung biopsy of in a
DWI-restricted consolidation for a suspected lung lymphoma.
The histological pattern showed multifocal interstitial lym-
phoid infiltrates spreading into the alveolar septa and sur-
rounding airways and vessels, consistent with LIP
(Supplementary Fig. 1).
Newly Diagnosed Patients Patients (n. 4, 9), who started
IVIG replacement therapy at the study time, had a second lung
MRI assessment and PFTs 12 months after starting Ig
treatment. FEV1 improved in both patients (+8 and +7 %,
respectively) as well as total parenchymal and total bronchial
scores (Supplementary Fig. 2). RepresentativeMRI sequences
in a patient before and 12 months after Ig administration were
shown in (Fig. 6).
Discussion
In this study, we demonstrated that MRI with DWI identified
lung inflammatory lesions in patients with PAD. Moreover, we
confirmed our previous data on the non-inferiority of MRI vs
HRCT scan [29]. HRCT is the gold standard in the lung struc-
tural damage evaluation for its excellent spatial resolution, fast
acquisition times and wide availability [30]. However, HRCT
poses concerns regarding the radiation dose, mostly in CVID
patients, a populationwith a suggested increased radio sensitivity
undergoing a long life follow-up [14–19]. Therefore, for these
subjects, radiation-free imaging would be desirable for both
follow-up and therapy monitoring. Nowadays, several strategies
have been developed to overcome the inherent technical limita-
tions of lung MRI and this imaging modality is becoming a
promising tool in different diseases, including primary immune
deficiencies such as ataxia-telangiectasia [31]. The implementa-
tion of DWI sequences enabled the acquisition of valuable in-
formation regarding the microstructure of tissues, allowing the
identification of several pathological processes, including active
inflammation [21–24, 32, 33]. In a previous cross-sectional
Fig. 5 Representative MRI with
DWI sequences: nodules Nodules
detected by MRI with DWI. MRI
BLADE sequence detecting a
nodule (white arrow) at the right
lower lobe (a) without a DWI
corresponding hotspot (b). MRI
BLADE sequence detecting
multiple and bilateral small
nodules of the lower lobes (c) and
their corresponding hotspots at
DWI assessment (white arrow)
(d)
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study, we have demonstrated that MRI with BLADE sequences
was a reliable technique in the detection of bronchial and paren-
chymal alterations and provided information overlapping HRCT
[20].We confirmed our previous data andwe showed high levels
of concordance between HRCT and MRI in scoring bronchiec-
tasis severity, extent of bronchiectasis and mucus plugging.
However, HRCT had a higher capacity to identify the involve-
ment of bronchial generation up to the fifth and distal. We
showed here that the inclusion of DWI sequences might provide
valuable records to detect the presence of areas of active inflam-
mation. Other radiological procedures, such as Positron
Emission Tomography-CT, have been proposed for localization
and quantification of active inflammation in the lung [34, 35].
However, their use is restricted by high ionizing radiation expo-
sure, cost and limited availability.
For DWI image analysis, we used an adapted Bhalla scoring
system taking into account all the alterations showing equal or
higher signal intensity compared to the spinal cord at the
highest b value. This technique, already adopted in previous
experiences [36], did not imply a quantitative analysis derived
from Apparent Diffusion Coefficient maps, it is hardly adapt-
able to lung imaging for its low proton density, B0 inhomoge-
neity, and physiologic motion. Moreover, the presence of sus-
ceptibility artefacts would lead to difficulty and poor reproduc-
ibility in selecting a consistent region of interest.
In this cohort, MRI protocol was able to identify lung alter-
ations occurring in PAD patients; our results showed that a semi-
quantitative assessment with a scoring system was feasible and
matched well with the total mean HRCT scores and PFTs of the
same patients. In our cohort, the MRI evaluation showed that
bronchial abnormalities were the prevalent finding in PAD pa-
tients. These abnormalities might be considered as signs of
chronic, active inflammation and/or infections. [1–5]. Thus, as
previously suggested [3] aside from Ig replacement, a strategy to
reduce the chronic mucosal damage should be defined. Chronic
antibiotics treatment was suggested but its efficacy is still matter
of discussion [37]; now we are conducting a large double blind
study about prophylaxis with azithromycin in PAD in order to
prove a possible benefit in reducing respiratory exacerbations as
shown in patients with non-cystic fibrosis bronchiectasis [38].
Fig. 6 Representative MRI
sequences in a patient at diagnosis
and after 12 months In a 18 years
old man who started Ig
replacement therapy (patient n. 4),
MRI BLADE sequence at first
MRI showed multiple distal
mucus plugs with branching
patterns (“tree in bud”
appearance) of the left upper lobe
(white arrows) (a); these
abnormalities regressed at the
second MRI assessment after
12 months (white arrows) (b).
MRI BLADE sequence at first
MRI showed one nodule (white
arrow) at the right lower lobe (c);
the nodule showed a reduction in
size at the second MRI
assessment after 12 months
(white arrow) (d)
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Even if Ig therapy could not reduce the progression of lung
diseases and damage, we documented an improvement of paren-
chymal and bronchial scores and of PFTs in newly diagnosed
PAD patients after the beginning of Ig replacement therapy. We
found a significant relationship between the extent of MRI bron-
chial abnormalities score and PFTs. Based on these findings, it
appears that PFTs alterations were strictly connected to a bron-
chial damage. However, MRI parenchymal scores did not corre-
late with PTFs, including DLCO. This was not surprising since
none of the patients enrolled had bullae, only few patients had a
mild emphysema and none had clinical signs of acute pulmonary
infection at the time of the study. Moreover, MRI was able to
identify active bronchial abnormalities in a group of patients with
normal PFTs. The interpretation of DWI findings may represent
a useful tool in addition to the conventional morphological anal-
ysis, mostly in subjects with advanced disease. In our evaluation,
all DWI hotspots corresponded to morphological alterations, but
not vice versa: lung pathological findings showed different DWI
patterns or no DWI signal at all. It can be postulated that the
mismatch between DWI and morphological data correlates with
cellular and extra-cellular space modifications (density/composi-
tion/water content) induced by active inflammation: these phe-
nomena may affect DWI even before macroscopic alterations
can be detected on conventional imaging. DWI parenchymal
restricted areas were mainly detected in patients with severe total
and parenchymal scores and with more severe alterations of
PFTs. They were associated with abnormalities described in pa-
tients with the inflammatory CVID phenotypes: systemic gran-
ulomatous disease, systemic lymphadenopathy, expansion of
CD21low B cells [39]. For these reasons, DWI might represent
a marker of disease activity and it could be used during follow-
up of PAD patients in order to distinguish foci of active
inflammation/sub-clinically progressive lung disease from
chronic pathological manifestations [8–11]. The presence of in-
flammation represents an important pathological process under-
lying many lung morphological alterations in PAD patients and,
in the clinical practice, it is important to determine the activity of
disease to guide interventions. DWI sequences, with the possible
identification of active inflammation, may allow an early dis-
crimination of patients with infective/inflammatory or non-infec-
tive/inflammatory disease. Inflammatory lung diseases in CVID
have been reported to be associated with lung disease progres-
sion and increased mortality [11, 40, 41], but the timing when
starting an immunosuppressive treatment is still open [42–44].
Moreover, since MRI is a radiation-free technique, it can be
repeatedly used in follow-up monitoring of treatment response,
differentiating between active and fibrotic lesions.
Conclusions
Clinicians might consider MRI with DWI in the diagnostic
algorithm of pulmonary lesions as a non-invasive, radiation-
free method complementary to other diagnostic tools. Our
results might help to define the role of morphological MRI
sequences and DWI sequences in the diagnosis of foci of
active inflammation and/or sub-clinically progressive lung
disease. The major limit of this study was the lack of informa-
tion on bronchoalveolar lavages and the presence of a single
DWI restricted lung biopsy. Future studies could likely benefit
from the longitudinal evaluation of larger cohorts of patients
with primary immune deficiencies or other clinical conditions
requiring a frequent ionizing radiation exposure in order to
assess the potential use of DWI to select biopsy areas and to
monitor the response to treatment in non-infective inflamma-
tory disease.
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